Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges

The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients

(2018) Vyara Matson et al.   SCIENCE

High response rate to PD-1 blockade in desmoplastic melanomas

(2018) Zeynep Eroglu et al.   NATURE

ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer

(2017) Christian Marth et al.   EUROPEAN JOURNAL OF CANCER

CD4 + T Cell Activation and Vascular Normalization: Two Sides of the Same Coin?

(2017) Michele De Palma et al.   IMMUNITY

Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy

(2017) Keehoon Jung et al.   JOURNAL OF CLINICAL INVESTIGATION

Effect of angiotensin system inhibitors on survival in newly diagnosed glioma patients and recurrent glioblastoma patients receiving chemotherapy and/or bevacizumab

(2017) Victor A. Levin et al.   JOURNAL OF NEURO-ONCOLOGY

Severe cerebral edema following nivolumab treatment for pediatric glioblastoma: case report

(2017) Xiao Zhu et al.   Journal of Neurosurgery-Pediatrics

CDK4/6 inhibition triggers anti-tumour immunity

(2017) Shom Goel et al.   NATURE

Elements of cancer immunity and the cancer–immune set point

(2017) Daniel S. Chen et al.   NATURE

Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming

(2017) Lin Tian et al.   NATURE

Monitoring immune-checkpoint blockade: response evaluation and biomarker development

(2017) Mizuki Nishino et al.   Nature Reviews Clinical Oncology

Therapeutic targeting of the angiopoietin–TIE pathway

(2017) Pipsa Saharinen et al.   NATURE REVIEWS DRUG DISCOVERY

OS10.3 Randomized Phase 3 Study Evaluating the Efficacy and Safety of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: CheckMate 143

(2017) D. A. Reardon et al.   NEURO-ONCOLOGY

Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastoma

(2017) Lei Qin et al.   NEURORADIOLOGY

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2017) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

(2017) Scott J. Antonia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting CXCR4-dependent immunosuppressive Ly6Clowmonocytes improves antiangiogenic therapy in colorectal cancer

(2017) Keehoon Jung et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Role of vascular normalization in benefit from metronomic chemotherapy

(2017) Fotios Mpekris et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

(2017) V. Gopalakrishnan et al.   SCIENCE

Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

(2017) Bertrand Routy et al.   SCIENCE

Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade

(2017) Martina Schmittnaegel et al.   Science Translational Medicine

Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation

(2017) Elizabeth Allen et al.   Science Translational Medicine

Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy

(2017) Matthias Pinter et al.   Science Translational Medicine

Direct Effects of Anti-Angiogenic Therapies on Tumor Cells: VEGF Signaling

(2017) Thomas Simon et al.   TRENDS IN MOLECULAR MEDICINE

Independent predictors of overall survival and recurrence in biphenotypic hepatocellular cancer.

(2017) Manik Amin et al.   JOURNAL OF CLINICAL ONCOLOGY

A randomized phase 2, single-blind study of temozolomide (TMZ) and radiotherapy (RT) combined with nivolumab or placebo (PBO) in newly diagnosed adult patients (pts) with tumor O6-methylguanine DNA methyltransferase (MGMT)-methylated glioblastoma (GBM)—CheckMate-548

(2016) M. Weller et al.   ANNALS OF ONCOLOGY

Evaluation of Angiopoietin-2 as a biomarker in gastric cancer: results from the randomised phase III AVAGAST trial

(2016) Ulrich T Hacker et al.   BRITISH JOURNAL OF CANCER

Normalization of Tumor Vessels by Tie2 Activation and Ang2 Inhibition Enhances Drug Delivery and Produces a Favorable Tumor Microenvironment

(2016) Jin-Sung Park et al.   CANCER CELL

Angiopoietin-2 May Be Involved in the Resistance to Bevacizumab in Recurrent Glioblastoma

(2016) Marianne Labussière et al.   CANCER INVESTIGATION

CCL2 Produced by the Glioma Microenvironment Is Essential for the Recruitment of Regulatory T Cells and Myeloid-Derived Suppressor Cells

(2016) Alan L. Chang et al.   CANCER RESEARCH

Efficacy of Cotargeting Angiopoietin-2 and the VEGF Pathway in the Adjuvant Postsurgical Setting for Early Breast, Colorectal, and Renal Cancers

(2016) Florence T.H. Wu et al.   CANCER RESEARCH

The Basis of Oncoimmunology

(2016) A. Karolina Palucka et al.   CELL

Targeting regulatory T cells in tumors

(2016) Chang Liu et al.   FEBS Journal

Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2

(2016) Bradley J. Monk et al.   GYNECOLOGIC ONCOLOGY

A Rosier Picture for Young Women With Breast Cancer

(2016) Ellen Warner   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial

(2016) Gérard Zalcman et al.   LANCET

Obesity and Cancer: An Angiogenic and Inflammatory Link

(2016) Dai Fukumura et al.   MICROCIRCULATION

Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma

(2016) A. Ilhan-Mutlu et al.   MOLECULAR CANCER THERAPEUTICS

Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages

(2016) Teresa E. Peterson et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival

(2016) Jonas Kloepper et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases

(2016) N. N. Rahbari et al.   Science Translational Medicine

Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell–driven rejection of high-grade glioma

(2016) Abhishek D. Garg et al.   Science Translational Medicine

Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy

(2016) Xinqi Wu et al.   Cancer Immunology Research

The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment

(2016) Shona A. Hendry et al.   Frontiers in Immunology

Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma

(2015) A. Scholz et al.   EMBO Molecular Medicine

CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice

(2015) Yunching Chen et al.   HEPATOLOGY

Obesity and cancer immunotherapy toxicity

(2015) Annie Mirsoian et al.   Immunotherapy

Lessons From Anti–Vascular Endothelial Growth Factor and Anti–Vascular Endothelial Growth Factor Receptor Trials in Patients With Glioblastoma

(2015) Christine Lu-Emerson et al.   JOURNAL OF CLINICAL ONCOLOGY

VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors

(2015) Thibault Voron et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Impact of bevacizumab administered dose on overall survival of patients with progressive glioblastoma

(2015) Victor A. Levin et al.   JOURNAL OF NEURO-ONCOLOGY

Non-angiogenic tumours unveil a new chapter in cancer biology

(2015) Francesco Pezzella et al.   JOURNAL OF PATHOLOGY

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

(2015) Alexander M M Eggermont et al.   LANCET ONCOLOGY

Improved Treatment Efficacy of Antiangiogenic Therapy when Combined with Picornavirus Vaccination in the GL261 Glioma Model

(2015) Danielle N. Renner et al.   Neurotherapeutics

Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer

(2015) Rebecca S. Heist et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients

(2015) Sara M. Tolaney et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeting Vascular Pericytes in Hypoxic Tumors Increases Lung Metastasis via Angiopoietin-2

(2015) Doruk Keskin et al.   Cell Reports

Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results

(2015) Asim Amin et al.   Journal for ImmunoTherapy of Cancer

The Role of Mechanical Forces in Tumor Growth and Therapy

(2014) Rakesh K. Jain et al.   Annual Review of Biomedical Engineering

Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia

(2014) Rakesh K. Jain   CANCER CELL

Postsurgical Adjuvant Tumor Therapy by Combining Anti-Angiopoietin-2 and Metronomic Chemotherapy Limits Metastatic Growth

(2014) Kshitij Srivastava et al.   CANCER CELL

A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma

(2014) Mark R. Gilbert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

(2014) Olivier L. Chinot et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with Bevacizumab in Advanced Cervical Cancer

(2014) Krishnansu S. Tewari et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evaluation of Potentially Predictive Markers for Anti-Angiogenic Therapy with Sunitinib in Recurrent Ovarian Cancer Patients

(2014) Dirk O Bauerschlag et al.   Translational Oncology

Role of Angiopoietin-2 in Adaptive Tumor Resistance to VEGF Signaling Blockade

(2014) Nicolò Rigamonti et al.   Cell Reports

Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma

(2014) F. S. Hodi et al.   Cancer Immunology Research

Location, location, location: functional and phenotypic heterogeneity between tumor-infiltrating and non-infiltrating myeloid-derived suppressor cells

(2014) Sarah K Maenhout et al.   OncoImmunology

A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma

(2013) M Peeters et al.   BRITISH JOURNAL OF CANCER

Neuropilin 1: function and therapeutic potential in cancer

(2013) Belal Chaudhary et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy

(2013) Y. Huang et al.   CANCER RESEARCH

Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effectin vivo

(2013) S. Yasuda et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy

(2013) Y. Kienast et al.   CLINICAL CANCER RESEARCH

Specificity redirection by CAR with human VEGFR-1 affinity endows T lymphocytes with tumor-killing ability and anti-angiogenic potency

(2013) W Wang et al.   GENE THERAPY

Oncology Meets Immunology: The Cancer-Immunity Cycle

(2013) Daniel S. Chen et al.   IMMUNITY

Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas

(2013) Jing Zeng et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Angiopoietin 2 mediates microvascular and hemodynamic alterations in sepsis

(2013) Tilman Ziegler et al.   JOURNAL OF CLINICAL INVESTIGATION

Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma

(2013) Tracy T. Batchelor et al.   JOURNAL OF CLINICAL ONCOLOGY

Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers

(2013) Rakesh K. Jain   JOURNAL OF CLINICAL ONCOLOGY

Effects of Vascular-Endothelial Protein Tyrosine Phosphatase Inhibition on Breast Cancer Vasculature and Metastatic Progression

(2013) Shom Goel et al.   JNCI-Journal of the National Cancer Institute

Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer

(2013) Hiroyuki Suzuki et al.   Journal of Translational Medicine

Combining two strategies to improve perfusion and drug delivery in solid tumors

(2013) T. Stylianopoulos et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels

(2013) Vikash P. Chauhan et al.   Nature Communications

The Calcineurin-NFAT-Angiopoietin-2 Signaling Axis in Lung Endothelium Is Critical for the Establishment of Lung Metastases

(2013) Takashi Minami et al.   Cell Reports

Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer

(2012) M. M. Eatock et al.   ANNALS OF ONCOLOGY

VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2

(2012) N G Gavalas et al.   BRITISH JOURNAL OF CANCER

AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney

(2012) Brian Rini et al.   CANCER

Rapid Decrease in Delivery of Chemotherapy to Tumors after Anti-VEGF Therapy: Implications for Scheduling of Anti-Angiogenic Drugs

(2012) Astrid A.M. Van der Veldt et al.   CANCER CELL

Angiopoietin-2 Functions as a Tie2 Agonist in Tumor Models, Where It Limits the Effects of VEGF Inhibition

(2012) C. Daly et al.   CANCER RESEARCH

Phase I trial of OTS11101, an anti-angiogenic vaccine targeting vascular endothelial growth factor receptor 1 in solid tumor

(2012) Hidetoshi Hayashi et al.   CANCER SCIENCE

Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab

(2012) P. S. Hegde et al.   CLINICAL CANCER RESEARCH

Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors

(2012) Hélène Salmon et al.   JOURNAL OF CLINICAL INVESTIGATION

Effects of Angiopoietin-2-Blocking Antibody on Endothelial Cell–Cell Junctions and Lung Metastasis

(2012) Tanja Holopainen et al.   JNCI-Journal of the National Cancer Institute

Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy

(2012) Y. Huang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases

(2012) D. P. Kodack et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia

(2012) S. J. Conley et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Combined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo

(2012) Kevin C. Foy et al.   OncoImmunology

Pericyte-Derived Sphinogosine 1-Phosphate Induces the Expression of Adhesion Proteins and Modulates the Retinal Endothelial Cell Barrier

(2011) Paul G. McGuire et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Angiopoietin-2 promotes myeloid cell infiltration in a  2-integrin-dependent manner

(2011) A. Scholz et al.   BLOOD

Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression

(2011) M. Franco et al.   BLOOD

HRG Inhibits Tumor Growth and Metastasis by Inducing Macrophage Polarization and Vessel Normalization through Downregulation of PlGF

(2011) Charlotte Rolny et al.   CANCER CELL

Targeting the ANG2/TIE2 Axis Inhibits Tumor Growth and Metastasis by Impairing Angiogenesis and Disabling Rebounds of Proangiogenic Myeloid Cells

(2011) Roberta Mazzieri et al.   CANCER CELL

Angiopoietin-2 drives lymphatic metastasis of pancreatic cancer

(2011) Petra Schulz et al.   FASEB JOURNAL

The brain tumor microenvironment

(2011) Nikki A. Charles et al.   GLIA

Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy

(2011) Benedetto Farsaci et al.   INTERNATIONAL JOURNAL OF CANCER

Angiopoietin 2 Stimulates TIE2-Expressing Monocytes To Suppress T Cell Activation and To Promote Regulatory T Cell Expansion

(2011) Seth B. Coffelt et al.   JOURNAL OF IMMUNOLOGY

Relation between bevacizumab dose intensity and high-grade glioma survival: a retrospective study in two large cohorts

(2011) Veronique Lorgis et al.   JOURNAL OF NEURO-ONCOLOGY

Cancer immunotherapy comes of age

(2011) Ira Mellman et al.   NATURE

Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells

(2011) Andrea Facciabene et al.   NATURE

Molecular mechanisms and clinical applications of angiogenesis

(2011) Peter Carmeliet et al.   NATURE

Normalization of the Vasculature for Treatment of Cancer and Other Diseases

(2011) Shom Goel et al.   PHYSIOLOGICAL REVIEWS

Endothelial focal adhesion kinase mediates cancer cell homing to discrete regions of the lungs via E-selectin up-regulation

(2011) Sachie Hiratsuka et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy

(2010) V Goede et al.   BRITISH JOURNAL OF CANCER

Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer

(2010) R. K. Shrimali et al.   CANCER RESEARCH

Autocrine VEGF Signaling Synergizes with EGFR in Tumor Cells to Promote Epithelial Cancer Development

(2010) Beate M. Lichtenberger et al.   CELL

Angiopoietin-2 Promotes Disease Progression of Neuroendocrine Tumors

(2010) K. M. Detjen et al.   CLINICAL CANCER RESEARCH

Angiopoietin-2 Interferes with Anti-VEGFR2-Induced Vessel Normalization and Survival Benefit in Mice Bearing Gliomas

(2010) S.-S. Chae et al.   CLINICAL CANCER RESEARCH

Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma

(2010) Tracy T. Batchelor et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival

(2010) Bernard Escudier et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206

(2010) Brian I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY

Angiopoietin-2 Levels Are Associated with Disease Progression in Metastatic Malignant Melanoma

(2009) I. Helfrich et al.   CLINICAL CANCER RESEARCH

Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients

(2009) J. S. Ko et al.   CLINICAL CANCER RESEARCH

Edema Control by Cediranib, a Vascular Endothelial Growth Factor Receptor–Targeted Kinase Inhibitor, Prolongs Survival Despite Persistent Brain Tumor Growth in Mice

(2009) Walid S. Kamoun et al.   JOURNAL OF CLINICAL ONCOLOGY

Cutting Edge: Vascular Endothelial Growth Factor-Mediated Signaling in Human CD45RO+ CD4+ T Cells Promotes Akt and ERK Activation and Costimulates IFN-  Production

(2009) A. Basu et al.   JOURNAL OF IMMUNOLOGY

Biomarkers of response and resistance to antiangiogenic therapy

(2009) Rakesh K. Jain et al.   Nature Reviews Clinical Oncology

Direct regulation of TWIST by HIF-1α promotes metastasis

(2008) Muh-Hwa Yang et al.   NATURE CELL BIOLOGY